Abstract 145P
Background
Glasgow prognostic score (GPS), which is defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2), has a prognostic significance in various malignant solid tumors. In a small-scale retrospective study, GPS was useful as a prognostic factor for chemo-naïve advanced biliary tract cancer (ABTC) patients with good performance status (PS; defined with ECOG PS 0 and 1). We evaluated whether GPS was useful in large-scale prospective study for ABTC patients with good PS.
Methods
ABTC patients with PS 0/1 and not missing laboratory data among the patients who received gemcitabine + cisplatin (GC) or GC + S-1 (GCS) in a phase III study (MITSUBA) were analyzed for factors with P < 0.2, using multivariate Cox proportional hazards model for overall survival (OS). In the exploratory analysis, OS was compared between GC and GCS according to GPS.
Results
Clinical data were collected from 230 patients (113 patients in the GC arm and 117 patients in the GCS arm) among 241 patients. The proportion of patients was 43% in GPS 0, 35% in GPS 1, and 22% in GPS 2, respectively. In the univariate and multivariate analyses, GPS was an independent prognostic factor (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.56-0.81; P < 0.001). The median OS was 18.0 months (95%CI, 15.3-20.7), 12.6 months (95%CI, 11.4-13.8), and 7.2 (95%CI, 4.4-10.0) for patients with GPS 0, GPS 1, and GPS 2, respectively. The HRs of GCS to GC were 1.00 (95%CI, 0.64-1.55; P = 0.99), 0.72 (95%CI, 0.45-1.15; P = 0.17), and 0.57 (95%CI, 0.32-1.04; P = 0.07), for patients with GPS 0, GPS 1, and GPS 2, respectively.
Conclusions
GPS was useful for chemo-naïve ABTC patients with good PS, and GCS might improve OS, especially in patients with poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kansai Hepato-Biliary Oncology Group.
Funding
Taiho Pharmaceutical.
Disclosure
T. Moriwaki: Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Lilly. Y. Yamamoto: Speaker Bureau / Expert testimony: Taiho. T. Yamada: Advisory / Consultancy: Taiho; Speaker Bureau / Expert testimony: Lilly. A. Taketomi: Honoraria (institution), Leadership role: Taiho. K. Yoshimura: Honoraria (self): Taiho; Honoraria (self): Lilly; Honoraria (self): Nippon Kayaku. E. Hatano: Honoraria (self): Taiho; Honoraria (self), Advisory / Consultancy: Lilly. T. Ioka: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract